Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Accounts Payables: 2022-2025

  • Abivax's Accounts Payables rose 90.10% to $65.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $65.1 million, marking a year-over-year increase of 90.10%. This contributed to the annual value of $46.8 million for FY2024, which is 7.83% down from last year.
  • Abivax's Accounts Payables amounted to $65.1 million in Q2 2025, which was up 9.46% from $59.5 million recorded in Q1 2025.
  • In the past 5 years, Abivax's Accounts Payables ranged from a high of $65.1 million in Q2 2025 and a low of $15.8 million during Q4 2022.
  • In the last 3 years, Abivax's Accounts Payables had a median value of $50.8 million in 2023 and averaged $51.3 million.
  • In the last 5 years, Abivax's Accounts Payables skyrocketed by 221.80% in 2023 and then decreased by 7.83% in 2024.
  • Abivax's Accounts Payables (Quarterly) stood at $15.8 million in 2022, then spiked by 221.80% to $50.8 million in 2023, then decreased by 7.83% to $46.8 million in 2024, then spiked by 90.10% to $65.1 million in 2025.
  • Its last three reported values are $65.1 million in Q2 2025, $59.5 million for Q1 2025, and $46.8 million during Q4 2024.